MATEON THERAPEUTICS AND WINDLAS BIOTECH ENTER INTO DEFINITIVE AGREEMENT TO COMMERCIALZE ARTIVEDA™ AGAINST COVID-19
November 11, 2020 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today an agreement with Windlas Biotech Pvt. Ltd. of...
MATEON TO PARTICIPATE IN MERIDIAN CLINICAL TRIALS SUMMIT
October 14, 2020 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, today announced...
MATEON THERAPEUTICS TO INITIATE COMMERCIALIZATION OF ARTISHIELD™.
October 05, 2020 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics “Mateon” (OTC.QB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, today announced that...
FDA Granted Pediatric Disease Designation for OXi-4503
September 16, 2020 07:00 ET
|
Mateon Therapeutics, Inc.
-Treatment of acute myeloid leukemia (AML) due to genetic mutations that disproportionately affect pediatric patients AGOURA HILLS, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics...
Company expands its management team to accelerate the commercialization and development of OT-101 for COVID-19
July 09, 2020 07:00 ET
|
Mateon Therapeutics, Inc.
- Stonegate Capital Partners Initiates Coverage on Mateon Therapeutics (MATN). Agoura Hills, California, July 09, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTC.QB: MATN), a late-stage...
Mateon Therapeutics Appoints Dr. Anthony Maida as Chief Clinical Officer - Translational Medicine
July 07, 2020 06:41 ET
|
Mateon Therapeutics, Inc.
Company expands its management team to accelerate the evaluation of OT-101 for Oncology and COVID-19 Agoura Hills, California, July 07, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTC.QB:...
Mateon Therapeutics Selects IQVIA for its Randomized, Controlled, Multi-Center Clinical Study to Test OT-101 as a Treatment for COVID-19 Patients
June 23, 2020 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, has selected IQVIA to manage C001, a Phase 2 randomized,...